Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: vaccine efficacy and the Delta and Delta Plus variants; breakthroughs in CRISPR gene editing and microbiome therapies; and the pandemic’s possible effect on regulatory pathways.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 2 July 2021, including: vaccine efficacy and the Delta and Delta Plus variants; breakthroughs in CRISPR gene editing and microbiome therapies; and the pandemic’s possible effect on regulatory pathways.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Vaccines Show Signs Of Efficacy Against Delta Variant, But Is It Enough?" - Scrip, 29 Jun, 2021.)
(Also see "Roche, Lilly Antibody Cocktails Threatened By Delta Plus Variant But More Evidence Needed" - Scrip, 25 Jun, 2021.)
(Also see "Intellia Achieves Gene-Editing Breakthrough With First In Vivo CRISPR Therapy" - Scrip, 28 Jun, 2021.)
(Also see "Amgen CEO Shines Light On Opportunities For Accelerated Drug Pathways" - Scrip, 28 Jun, 2021.)
(Also see "Ferring Chief Muses On Moment Of Truth For Microbiome Therapy" - Scrip, 24 Jun, 2021.)